Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1893 in Heart Failure With Preserved Ejection Fraction
NCT07269717Phase 2Recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-1893 in heart failure with preserved ejection fraction (HFpEF), sponsored by Shandong Suncadia Medicine Co., Ltd.. Started Mar 2026; status: recruiting.
02
Drugs
HRS-1893
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT07269717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07269717.